Report #2841700

Overview

Sex

Unknown

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

If I administered a dose intramuscularly instead of subcutaneously; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: If I administered a dose intramuscularly instead of subcutaneously). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 13-MAY-2025 Healthcare professional reported that if they administered a dose intramuscularly instead of subcutaneously which led to Subcutaneous injection formulation administered by other route. Anonymous Healthcare provider did not consent follow-up from Safety Department. No vaccination date, vaccine detail or patient demographics were obtained in this call.